Floatz logo

Epi-326

Epidermal Growth Factor Receptor

EpiBiologicsPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Epidermal Growth Factor Receptor cohort.

Asset / SponsorPhaseRating
Panobinostat
Dana-Farber Cancer Institute
Phase 2CCC

Same molecule, other indications

Epi-326 is also rated in:

Epidermal Growth Factor Receptor Gene MutationDormant
CC
Indicative ·
43 / 100
View asset →
head and neck squamous cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
head and neck cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →